Venus Remedies has received yet another Good Manufacturing Practices (GMP) approval from the Ethiopia Drug Administration and Control Authority (DACA) for four of its facilities, oncology liquid, and oncology lyophilized, dry powder cephalosporin and dry powder carbapenem.

The imported finished products in the country are less expensive compared to locally produced medication as there are nil or low import duties on products. Ethiopia is expected to become the third-largest sub-Saharan economy by 2023 and its GDP is expected to grow from $ 70 billion in 2008 to $ 472 billion by 2023, according to an Ernst & Young report of October 2009.

Venus possesses 59 international GMP certifications from different countries of the world for its nine super-speciality injectable manufacturing facilities.

Venus has filed 10 dossiers for oncology, cephalosproin and carbepenem products in Ethiopia. The registration will now be expedited after company registration and approval to be GMP compliant by their regulatory body DACA.

Venus Remedies Ltd is a research and development driven, pharmaceutical manufacturing company. Among the top 50 Indian Pharma companies of India, the company has out paced most Indian pharmaceutical companies in its growth and value creation over the past few years.